30-Nov-2010 - Takara Bio Inc.

MDxHealth Licenses Methylation Technology to Takara Bio Inc. for Scientific Research Market

MDxHealth SA announced that it has granted a non-exclusive worldwide license for its patented methylation specific PCR (MSP) technology to Takara Bio Inc..

Under the agreement, Takara Bio Inc. (Takara) has licensed the use of MDxHealth's MSP technology, the most widely applied methylation technology, for the scientific research market in exchange for an upfront fee plus royalties from future sales utilizing this technology. Other terms were not disclosed.

Facts, background information, dossiers
More about Takara Bio
  • News

    Takara Bio Europe Goes Direct in 2012

    Takara Bio Europe announced that it will start selling its range of Takara brand products exclusively and directly to customers in the UK, Germany, Austria and Switzerland, with immediate effect. The decision means customers will be able to buy both Takara and Clontech brand products from o ... more

    Clontech Laboratories & TET Systems Announce the Broadening of Their License Agreement

    Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems, a privately-held German biotech company based in Heidelberg, announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains r ... more

    Takara Bio to Acquire Clontech Unit of BD Biosciences

    Takara Bio Inc. announced that it has entered into a definitive agreement to acquire the Clontech unit ("Clontech") of BD Biosciences, mainly consisting of Clontech Laboratories Inc. (employees: 190), for USD $60 million (adjusted from USD $65 million due to the retention of certain invento ... more

  • Companies

    Takara Bio Europe S.A.S.

    Takara Bio Europe is a wholly owned subsidiary of Takara Bio Inc., who develops, manufactures, and distributes a wide range of life science reagents under the Takara™, Clontech®, and Cellartis® brands. Key products include SMART cDNA synthesis kits for a variety of samples and application ... more

More about MDxHealth
  • News

    MDxHealth acquires NovioGendix

    MDxHealth SA announced that it succesfully completed the acquisition of all of the shares in NovioGendix Holding B.V.. The completion of the acquisition took place on September 18, 2015. As part of the consideration that was paid for the shares in NovioGendix, the Company issued 1,086,956 n ... more

    MDxHealth's ConfirmMDx Genes Detect Clinically Significant Prostate Cancer

    MDxHealth SA announced that data demonstrating the prognostic value of its ConfirmMDx® for Prostate Cancer genes and technology was presented at the ASCO Genitourinary Cancers Symposium 2015.  The data support the ability to predict the presence of clinically significant cancer in biopsy-ne ... more

    MDxHealth Named Euronext Best BEL Small Company Performer for 2014

    MDxHealth SA announced that Euronext granted the 2014 Best BEL Small Company Award, for the highest return among its peers, to MDxHealth. The award was presented to Dr. Jan Groen, CEO of MDxHealth, by M. Pieter De Crem, Secretary of State for Foreign Trade, at a ceremony at the Palais de la ... more

  • Companies

    MDxHealth SA

    MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology based molecular diagnostic testing for personalized medicine. The company's tests are based on proprietary gene methylation technology and assist physicians and their patients with the accurate di ... more